Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
8.52 USD | +0.83% | -10.47% | +133.61% |
05-13 | Oppenheimer Adjusts Mind Medicine Price Target to $20 From $29, Maintains Outperform Rating | MT |
05-08 | Transcript : Mind Medicine Inc., Q1 2024 Earnings Call, May 08, 2024 |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+133.61% | 607M | |
+29.79% | 48.16B | |
-1.20% | 41.73B | |
+43.45% | 41.03B | |
-5.26% | 28.77B | |
+10.17% | 25.59B | |
-22.92% | 18.96B | |
+7.98% | 12.92B | |
+29.14% | 12.03B | |
-1.89% | 11.77B |
- Stock Market
- Equities
- MNMD Stock
- News Mind Medicine (MindMed) Inc.
- Mind Medicine (MindMed) Initiated at Outperform by RBC With $5 Price Target, Speculative Risk Qualifier; Firm Sees 'Opportunity for Upside'